Volitionrx - VNRX STOCK NEWS

VolitionRx (NYSE AMERICAN: VNRX) has signed an agreement with a leading pharmaceutical company to use its Nu.Q® Discover biomarkers in a longitudinal Phase 1/2b study. This marks the first human clinical study utilizing Volition's biomarkers with a pharmaceutical company sponsor.

The study will employ two Nu.Q® Discover assays to measure disease progression and treatment response, following a successful pilot study. The project is expected to span 12-18 months and generate significant revenue for Volition. The Nu.Q® Discover program offers drug developers rapid epigenetic profiling tools across various development stages.

Additional clinical studies are under discussion with this and other companies, potentially strengthening Volition's position in the pharmaco-epigenetics market. The biomarkers will be used to address an unmet medical need, though specific disease details were not disclosed.

VolitionRx (NYSE AMERICAN: VNRX) has announced its participation in the 97th Annual Western Veterinary Conference (WVC), scheduled for March 2-5, 2025, in Las Vegas. The conference, attracting approximately 20,000 veterinary professionals, will feature presentations about the company's Nu.Q® Vet Cancer Test.

The company will host three presentations by notable veterinary professionals: Dr. Sue Ettinger (Dr. Sue Cancer Vet), Dr. Brett Cordes, and Dr. Tom Butera. These sessions will focus on various aspects of the Nu.Q® Vet Cancer Test, including cancer journey navigation, practical implementation, and early detection screening. The test is designed to detect seven common cancers in dogs and is marketed as accessible, affordable, and easy-to-use with rapid results.

VolitionRx (NYSE AMERICAN: VNRX) has announced its first commercial sale of their High Throughput Synthetic Sepsis method, a breakthrough technology that measures Neutrophil Extracellular Traps (NETs) activation and inhibition in whole blood in real time. This innovative approach helps companies develop new therapeutics for sepsis and NETs-related diseases.

The technology addresses significant limitations in previous research by measuring NETs directly in whole blood, avoiding potential alterations in neutrophil responses caused by isolation procedures. The method provides a more physiologically relevant environment for studying neutrophil responses and enables precise measurement of NETs formation.

Sepsis, responsible for approximately 370,000 US deaths annually, involves NETs which are essential for trapping and neutralizing pathogens. However, their overproduction can lead to tissue damage and disease progression. This new technology aims to enhance understanding of conditions characterized by uncontrolled NETs formation and serve as a key tool in translational research.

VolitionRx (NYSE: VNRX) has announced a virtual investor event scheduled for February 14, 2025, at 8:00 AM ET. The event, titled 'Casting a New Light on Sepsis Management,' will feature presentations from Dr. Andrew Retter, Chief Medical Officer, and Gael Forterre, Chief Commercial Officer.

Dr. Retter will discuss Nu.Q® NETs H3.1, a novel biomarker for early mortality and organ dysfunction in sepsis, which also serves as an independent predictor for renal replacement therapy needs. Recent large-scale study results suggest potential clinical applications in risk stratification and early intervention for critically ill sepsis patients.

Mr. Forterre will provide updates on Volition's commercialization strategies through licensing and sales channels. The event will conclude with a live Q&A session.

VolitionRx (NYSE AMERICAN: VNRX) has announced significant results from a large-scale study of its Nu.Q®NETs H3.1 biomarker in sepsis patients. The study, analyzing plasma samples from 971 patients with sepsis and septic shock, demonstrates that the biomarker can independently predict 28-day mortality and need for renal replacement therapy.

The research reveals higher biomarker levels in septic shock compared to sepsis patients, showing a dose-response relationship with acute kidney injury severity. The study suggests Nu.Q® NETs H3.1's potential for risk stratification and early intervention in critically ill sepsis patients.

The company is currently engaged in commercial discussions with major diagnostic industry players, particularly focusing on the sepsis market. The technology aims to provide simple, cost-effective blood tests for disease diagnosis and monitoring in both humans and animals.

VolitionRx (NYSE AMERICAN: VNRX) has released its 2024 Business Review, highlighting significant achievements in expanding its diagnostic technologies. The company's Nu.Q® Vet Cancer Test reached 20 countries worldwide, with over 110,000 tests sold in the first three quarters of 2024.

Key developments include hosting a Satellite Symposium showcasing Nu.Q® NETs clinical utility in over 3,000 intensive care sepsis patients, strengthening their patent portfolio, and making progress in clinical and research programs within their cancer pillar. The company has initiated commercial discussions for out-licensing opportunities in sepsis and oncology liquid biopsy markets.

Volition also strengthened its Board of Directors with the appointment of Timothy Still as chair and Dr. Ethel Rubin as Independent Director, both bringing significant commercial and financing experience in diagnostics.

VolitionRx (NYSE AMERICAN: VNRX) has appointed LifeSci Advisors (LSA) as its investor relations consultants. The company, which specializes in epigenetics, made this announcement following significant progress in 2024, including the launch of Nu.Q® Vet Cancer Test in the U.S. and Europe through Antech.

The company plans to participate in the 14th Annual LifeSci Partners Corporate Access Event on January 15th, 2025, at the Beacon Grand Hotel in San Francisco, coinciding with the J.P. Morgan Health Care Conference. Volition anticipates multiple financial and value-creating operating milestones in human applications for both cancer and sepsis in 2025.

VolitionRx (NYSE AMERICAN: VNRX) announced results from an 800-patient study showing its Nu.Q® Cancer Test can differentiate between malignant and benign pulmonary nodules found by Low Dose CT (LDCT) scan in lung cancer screening. The study, led by Professor Jin-Shing Chen at National Taiwan University Hospital, revealed that a panel of two Nu.Q® nucleosome quantification assays achieved 92% diagnostic sensitivity and 89% Positive Predictive Value when combined with LDCT screening.

A 500-patient validation study in a real-world setting is planned to begin this year, with completion expected in 2025. If successful, the test could be included in Taiwan's National Lung Cancer Screening Program, potentially reducing unnecessary biopsies and surgeries for patients with benign nodules.

VolitionRx (NYSE AMERICAN: VNRX) has announced a registered direct offering expected to raise up to $1.9 million in gross proceeds. The offering includes the sale of 445,648 shares to company insiders at $0.5722 per share, and 2,857,389 shares with warrants to other investors at the same price.

The offering includes Form A warrants to purchase up to 2,857,389 shares at $0.5722 per share and Form B warrants for up to 1,428,693 shares at $0.71525 per share, both exercisable immediately with a 5-year expiration. If fully exercised, the warrants could generate additional gross proceeds of approximately $2.7 million.

The company plans to use the proceeds for research, product development, clinical studies, commercialization, and working capital.